| Kayla De Szendeffy, OTR/L | |
|
42211 N 41st Dr Ste 145, Anthem, AZ 85086-3812 | |
| (602) 808-9912 | |
| (602) 875-0385 |
| Full Name | Kayla De Szendeffy |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 42211 N 41st Dr Ste 145, Anthem, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063078152 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTH-007723 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kayla De Szendeffy, OTR/L 42211 N 41st Dr Ste 145, Anthem, AZ 85086-3812 Ph: (602) 808-9912 | Kayla De Szendeffy, OTR/L 42211 N 41st Dr Ste 145, Anthem, AZ 85086-3812 Ph: (602) 808-9912 |
News Archive
In a paper recently published in Pathogens, in silico affinity studies by researchers at the University of Illinois, USA, reveal several potential peptide binding sites required for HS-spike protein and ACE2-spike protein bond formation, and synthesis of suitable peptide inhibitors reveals impaired SARS-CoV-2 cell entry.
The National Institutes of Health has awarded researchers at University of California San Diego approximately $30 million over five years to expand and deepen longitudinal studies of the developing brain in children.
In a new study to asses patient awareness of medications prescribed during a hospital visit, 44% of patients believed they were receiving a medication they were not, and 96% were unable to recall the name of at least one medication that they had been prescribed during hospitalization. These findings are published today in the Journal of Hospital Medicine.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
› Verified 9 days ago
Kaitlyn Finnerty, M.S., OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 42211 N 41st Dr Ste 145, Anthem, AZ 85086 Phone: 602-808-9912 | |
Danielle Redding, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 42211 N 41st Dr Ste 145, Anthem, AZ 85086 Phone: 602-808-9912 | |
Mikaela Elyse Kirby, OTD, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 42211 N 41st Dr Ste 145, Anthem, AZ 85086 Phone: 602-808-9912 | |
Julie J Oyan, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 42103 N Anthem Heights Dr, Anthem, AZ 85086 Phone: 805-218-4294 | |
Callie Taylor, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 42015 N Venture Dr, Anthem, AZ 85086 Phone: 661-809-4351 | |
Eileen Ann Paulson, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 42211 N 41st Dr Ste 145, Anthem, AZ 85086 Phone: 630-946-8253 |